Comparative Pharmacology
Head-to-head clinical analysis: UNIPEN IN PLASTIC CONTAINER versus V CILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNIPEN IN PLASTIC CONTAINER versus V CILLIN.
UNIPEN IN PLASTIC CONTAINER vs V-CILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and peptidoglycan cross-linking.
Penicillin G (V-CILLIN) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin activation, leading to cell lysis.
250-500 mg intravenously or intramuscularly every 4-6 hours. Maximum dose 12 g per day.
250-500 mg orally every 8 hours or 500 mg every 12 hours for mild to moderate infections.
None Documented
None Documented
0.5-1 hour (normal renal function); prolonged to 2-5 hours in renal impairment
Terminal elimination half-life ~30-60 minutes in normal renal function; prolonged in renal impairment (up to 10 hours in anuria).
Renal: 60-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minor, <10%
Primarily renal (60-70% unchanged via tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic